Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
about
Recent progress in pancreatic cancerCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansImaging preoperatively for pancreatic adenocarcinomaNew challenges in perioperative management of pancreatic cancerRadical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a CaseA Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.Percutaneous ultrasound-guided core needle biopsy of solid pancreatic masses: Results in 250 patients.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: A retrospective analysis by the Association Française de Chirurgie.First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Pancreatic cancer-improved care achievablePost-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology GuidelinesS-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerDoes the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinomaEfficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancerResection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationshipsPhase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinomaBaseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma.A prospective, randomized trial of pancreatectomy combined with isolated hepatic perfusion via a dual route or conventional postoperative adjuvant therapy in patients with advanced pancreatic head carcinoma.Quality appraisal of clinical practice guidelines on pancreatic cancer: a PRISMA-compliant article.Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular InvolvementInverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic ManagementMultimodality treatment of recurrent pancreatic cancer: Mith or reality?Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic CancerResponse evaluation following neoadjuvant treatment of pancreatic cancer patientsRandomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final resultsComparison of Multidetector CT and Gadobutrol-Enhanced MR Imaging for Evaluation of Small, Solid Pancreatic Lesions.Current status of chemotherapy for the treatment of advanced biliary tract cancer.Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.Pancreatic ductal adenocarcinoma staging.Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancerBiomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.
P2860
Q24626346-4DF2B212-80F9-467C-8A67-3B7791130DF3Q26767041-E29B78DE-0DF2-4FAD-837B-B1B9663910A5Q26799450-EB0711C5-7227-46A9-B0C4-A271BFD071F8Q28082422-F94C4909-B6DB-4994-BE9C-6EFEDB5CDDE1Q28388329-92076984-B172-4B6E-96B1-2D9557A0385BQ30238706-6BA52B71-83E4-4B5F-9AE7-8128D766A110Q33167097-151EC893-08C3-4B5F-8CF2-C00A30708953Q33558951-9DF39C83-4C15-4A96-A7EF-C3D22FFAA9D7Q33818221-4902DA56-67D6-4042-9AA0-7A7153DFA2B2Q34008520-9F253F98-45CB-48F0-968E-A1C822FD4AE7Q34036659-17D5F331-54CC-40B6-8154-5DCF427C2638Q34127306-1A33B59E-88F0-4B20-8E18-DF24DDBED516Q34326711-B6A6DA05-BC9F-40EF-A3F6-E11372001C7EQ34539541-31080627-CBD0-4ED2-8451-2BD3BCF019A4Q34892858-60274C05-ACDD-44A1-9106-299017B17033Q34941883-FBEDEF96-6418-48C3-992A-DDFED34AD78DQ35028999-1AFB46A4-7234-4297-8B6F-544F362358FBQ35118758-6C33D6EA-5F32-47BC-B6C9-3383B197C339Q35147520-F3725133-44A5-4403-956F-593ADF4870CDQ35155573-5B97B157-89EE-45D2-AF3D-E7974A793AB3Q35202400-2DF65FE7-3701-4AD3-BDAA-ADE732A343D1Q35213015-4420AAF9-1200-42EA-9E9E-BF64D018074AQ35339214-F6A0BEF4-962A-4F81-951D-637BD6E15917Q35679643-EBF875B9-659F-41E4-A035-AB9DCDCFDD36Q35791513-88BCBE8D-5C97-4CA2-AC50-0B571447AD09Q36009104-89AEE657-984A-48FE-A28F-F1D725517D59Q36099266-E00D0ECD-178A-4340-A4C4-ED94BAC4EB33Q36194657-624829CB-A81E-4930-AC33-D4BFCB8C679EQ36195812-D9A43C91-32FD-49D6-8828-4ED4DAC08EB4Q36281575-44EBE9A5-4279-4E83-865C-0B6BE0B27DB2Q36369834-AC35299F-275C-46F8-873C-8DACC499638BQ36540475-DB8AAAFF-5656-4F19-9F80-A4AF6941B06BQ36693226-99DD28B6-EB50-4907-A25F-B19826BF6B97Q36764997-859AD65A-7B65-403C-BBA7-521E71D93825Q37073536-A5FB0887-9DDB-42CA-83EC-E7F247E616B3Q37138732-55DA089E-39EC-4232-B144-0051770FAA4EQ37151112-AD463296-56DF-4093-A808-A5064ED83199Q37193819-2537DDD8-7541-43F7-AE6A-A3A3F3A3B64BQ37357401-6F5CFEC1-DDEB-4FB8-B082-F55FCEECD4E9Q37413146-A71FFFA5-13F9-40BC-AC7D-49C61F377D7A
P2860
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
@en
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
@nl
type
label
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
@en
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
@nl
prefLabel
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
@en
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
@nl
P2093
P2860
P50
P356
P1476
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines
@en
P2093
Aaron R Sasson
Al B Benson
Anitra Tally
Brian Czito
Brian M Wolpin
Deborah A Freedman-Cass
Dorothy A Shead
Edgar Ben-Josef
Ephraim S Casper
P2860
P304
P356
10.6004/JNCCN.2012.0073
P577
2012-06-01T00:00:00Z